Therapeutic effect of Budigerfo inhalation aerosol combined with non-invasive positive pressure ventilation in the treatment of acute exacerbation of COPD
Objective:To analyze the curative effect of budigerfol inhalation aerosol combined with non-invasive positive pressure ventilation(NIPPV)in the treatment of acute COPD exacerbation(AECOPD).Methods:The clinical data of 84 patients with AECOPD who were treated in our hospital from June 2021 to June 2023 were retrospectively collected.According to different treatment methods,patients were divided into control group(budesonide inhalation aerosol treatment+NIPPV treatment,42 cases)and observation group(Budesonide inhalation aerosol treatment+NIPPV treatment,42 cases).After 7 days of treatment,the arterial blood gas indexes before and after treatment were compared between the two groups:Pondus Hydrogenii(pH),Partial pressure of oxygen(PaO2),Partial pressure of carbon dioxide(PaCO2);inflammatory factors:C-reactive protein(CRP),procalcitonin(PCT),interleukin-6(IL-6);pulmonary function:Forced Vital Capacity(FVC),Forced Expiratory Volume in 1 second(FEV1),Peak Expiratory Flow(PEF),and adverse reactions during treatment were recorded.Results:Compared with before treatment,the levels of pH,PaO2,FVC,FEV1,and PEF in both groups increased,while the levels of PaCO2,PCT,IL-6,and CRP decreased(P<0.05).Among them,the levels of pH,PaO2,FVC,FEV1,and PEF in the observation group increased more significantly,while the levels of PaCO2,PCT,IL-6,and CRP decreased more significantly(P<0.05).The incidence of adverse reactions in observation group was significantly lower than that in control group(P<0.05).Conclusion:The treatment of AECOPD patients with Budigerfo inhalation aerosol combined with NIPPV can improve the level of arterial blood gas,relieve inflammation,enhance lung function,and reduce adverse reactions.
NETL
NSTL
万方数据
